Retatrutide FDA Approval Status: July 2026 Update

What's New: July 2026 Update

• TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients — Eli Lilly's pivotal Phase 3 obesity trial met all primary and key secondary endpoints
• 45.3% of patients on 12mg lost ≥30% of body weight — surgical-level outcomes confirmed in the largest retatrutide trial to date
• 104-week extension: patients with BMI ≥35 reached up to 30.3% average weight loss — weight loss did not plateau at 80 weeks
• TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First completed Phase 3 trial in type 2 diabetes — up to -2.0% HbA1c reduction and 16.8% weight loss in 537 patients, a separate program from TRIUMPH
• OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a baseline of 58.6 events/hour
• NDA on track: Industry estimates continue to expect Q4 2026 filing following TRIUMPH-1 and TRIUMPH-4 data
• TRIUMPH-2 and TRIUMPH-3 results still expected later in 2026 — this page updates monthly

Current Status: Where Things Stand

Retatrutide is an investigational medication developed by Eli Lilly. It is not FDA approved and not available by prescription as of July 2026.

As of this update, three Phase 3 programs have reported results. TRIUMPH-4 demonstrated 28.7% average weight loss at 68 weeks (December 2025). TRIUMPH-1 confirmed 28.3% at 80 weeks in 2,339 patients (May 21, 2026) — results consistent with bariatric surgery outcomes. And TRANSCEND-T2D-1, part of a separate three-trial diabetes-specific program, confirmed -2.0% HbA1c reduction and 16.8% weight loss in 537 type 2 diabetes patients (topline March 2026, published in The Lancet, June 2026).

TRIUMPH-1's nested sleep apnea substudy also reported positive data at the ADA Scientific Sessions on June 6, 2026, showing a 60.6% reduction in the apnea-hypopnea index (AHI) from a severe-OSA baseline of 58.6 events per hour.

Eli Lilly now has the primary efficacy dataset required for an NDA filing, which remains expected before the end of 2026 pending TRIUMPH-2 data.

TRIUMPH Trial Program: Full Status

Key context: TRIUMPH-1 and TRIUMPH-4 form the primary efficacy package for the NDA filing. TRIUMPH-2 will support a potential combined obesity-and-diabetes indication. TRANSCEND-T2D-1 is part of a separate three-trial diabetes-specific program — it confirms retatrutide's efficacy in a dedicated T2D population, distinct from TRIUMPH-2's obesity-with-diabetes enrollment. TRIUMPH-Outcomes is not required for initial obesity approval but will be critical for long-term payer and labeling decisions.

FDA Approval Timeline: Step by Step

Timeline assumes standard FDA review (10–12 months) with no unexpected safety signals. If priority review designation is granted, approval could come approximately 4 months earlier.

What to Watch in the Second Half of 2026

With TRIUMPH-1, TRANSCEND-T2D-1, and the TRIUMPH-1 OSA substudy all now confirmed, the remaining milestones in 2026 are TRIUMPH-2 and TRIUMPH-3 — and the NDA submission that follows them.

TRIUMPH-2 (expected Q3–Q4 2026)

TRIUMPH-2 enrolls approximately 1,400 adults with both obesity and type 2 diabetes. Unlike TRANSCEND-T2D-1, which specifically targeted a diabetes population, TRIUMPH-2 is a weight management basket trial where participants also have T2D — a distinct enrollment design. Results here will determine whether retatrutide can pursue a combined obesity-and-diabetes indication on its label, which matters commercially: diabetes coverage by Medicare and most commercial insurers is substantially broader than obesity-only coverage.

TRIUMPH-3 (expected later 2026)

TRIUMPH-3 enrolls adults with obesity and established cardiovascular disease — not sleep apnea, as some sources have incorrectly described it. Results will provide the CVD safety picture for the portion of the target population with pre-existing heart disease, and may support a cardiovascular complication indication alongside obesity.

NDA filing (Q4 2026)

With TRIUMPH-1 and TRIUMPH-4 both positive, Lilly has the primary efficacy dataset required for submission. The NDA is expected before year-end, with TRIUMPH-2 data providing additional support for the diabetes indication.

What This Means for Patients

If you are waiting for retatrutide: it will not be available by prescription before late 2027 at the absolute earliest, and realistically Q1–Q2 2028. Waiting means delaying obesity treatment by 18–24 months.

If you qualify for existing medications — tirzepatide (Zepbound, 22.5% average weight loss) or semaglutide (Wegovy, 14.9% average weight loss) — the clinical case for waiting is weak. Starting treatment now with an approved medication, then reassessing in 2028, is the approach most obesity specialists recommend.

If you want to access retatrutide before approval: the only legal pathway is clinical trial enrollment. Check ClinicalTrials.gov for ongoing TRIUMPH trials or extension studies. Most require BMI ≥30, no prior bariatric surgery, and stable weight for 3+ months. You may be randomized to placebo — a 50% chance in most trials.

If you are already on tirzepatide or semaglutide: there is no mechanism to switch to retatrutide at this time. Continue current treatment and monitor results through the second half of 2026 — TRIUMPH-2 data will clarify whether a switch in 2028 makes clinical sense for your situation.

Sources & References

• Eli Lilly. TRIUMPH-1 OSA substudy results. Presented at ADA 86th Scientific Sessions. June 6, 2026.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• Bajaj HS, et al. Efficacy and safety of retatrutide (TRANSCEND-T2D-1). The Lancet, 2026.
• Giblin K, Kaplan LM, Somers VK, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026;28(1):83-93.
• Jastreboff AM, et al. TRIUMPH-4 Phase 3 Results. N Engl J Med. December 2025.
• Jastreboff AM, et al. Retatrutide Phase 2. N Engl J Med. 2023;389:514–526.
• ClinicalTrials.gov: TRIUMPH program registry entries.
• FDA guidance: Developing Products for Weight Management (2022).

Medical Disclaimer: This article is for informational purposes only. Retatrutide is investigational and not FDA approved. Consult your healthcare provider before making any treatment decisions.